ProKidney Corp.
Clarence W. Baker has extensive experience in quality assurance and information technology, currently serving as the Director of IT GxP Assurance & Compliance and Director of Quality Assurance - Systems Technology at ProKidney Corp. since July 2022. As President/CEO of Quality Consulting Services, LLC since December 2017, Clarence has demonstrated leadership in quality consulting. Prior roles include Sr. Quality Administrator at doTERRA International LLC, Director of Quality Operations at Castle Creek Biosciences, Inc., and various positions in quality technology and information systems at companies such as Advanced Accelerator Applications, Endocyte, and Cognate BioServices, among others. With a strong background in quality technology and compliance, Clarence has contributed significantly to operational excellence in different sectors, including biotechnology and pharmaceuticals.
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.